These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28003217)

  • 1. The Early Clinical Response Endpoint: Great Timing by the Food and Drug Administration?
    Talbot GH
    Clin Infect Dis; 2017 Jan; 64(2):218-220. PubMed ID: 28003217
    [No Abstract]   [Full Text] [Related]  

  • 2. Understanding Early and Late Endpoints in Registrational Trials of Community-acquired Bacterial Pneumonia.
    Talbot GH
    Clin Infect Dis; 2021 Nov; 73(9):e2613-e2615. PubMed ID: 32584958
    [No Abstract]   [Full Text] [Related]  

  • 3. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.
    Talbot GH; Powers JH; Fleming TR; Siuciak JA; Bradley J; Boucher H;
    Clin Infect Dis; 2012 Oct; 55(8):1114-21. PubMed ID: 22744885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good.
    Corey GR; Stryjewski ME
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S469-76. PubMed ID: 21546623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials.
    Itani KM; Shorr AF
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S4-9. PubMed ID: 24343831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.
    Maggiore C; Pasquale T; Cole P; Friedland HD
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):141-53. PubMed ID: 25467425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
    Guervil DJ; Kaye KS; Hassoun A; Cole P; Huang XY; Friedland HD
    J Chemother; 2016 Jun; 28(3):180-6. PubMed ID: 25817579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review and Meta-Analysis To Estimate Antibacterial Treatment Effect in Acute Bacterial Skin and Skin Structure Infection.
    Cates JE; Mitrani-Gold FS; Li G; Mundy LM
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4510-20. PubMed ID: 25987628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Jorgenson MR; DePestel DD; Carver PL
    Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).
    Amara S; Adamson RT; Lew I; Huang X
    Curr Med Res Opin; 2013 Jul; 29(7):869-77. PubMed ID: 23659559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summary of ceftaroline fosamil clinical trial studies and clinical safety.
    File TM; Wilcox MH; Stein GE
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S173-80. PubMed ID: 22903949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
    Casapao AM; Steed ME; Levine DP; Rybak MJ
    Expert Opin Pharmacother; 2012 Jun; 13(8):1177-86. PubMed ID: 22594846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
    Van Wart SA; Forrest A; Khariton T; Rubino CM; Bhavnani SM; Reynolds DK; Riccobene T; Ambrose PG
    J Clin Pharmacol; 2013 Nov; 53(11):1155-67. PubMed ID: 23907740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging drugs for acute bacterial skin and skin structure infections: an update.
    Kollipara R; Downing C; Lee M; Guidry J; Curtis S; Tyring S
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):431-40. PubMed ID: 25146459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early response of ceftaroline fosamic in the treatment of soft-tissue infections.
    Giuliano C; Kale-Pradhan PB; Johnson LB
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):509-12. PubMed ID: 23121271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update for community-acquired bacterial pneumonia pharmacotherapy: what's new and where does it fit?
    DeBellis HF; Jones MC; Kincaid SE
    J Pharm Pract; 2012 Dec; 25(6):569-75. PubMed ID: 23065389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
    Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS
    J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review.
    Lee JS; Giesler DL; Gellad WF; Fine MJ
    JAMA; 2016 Feb; 315(6):593-602. PubMed ID: 26864413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients.
    Evans JD; Udeani G; Cole P; Friedland HD
    Postgrad Med; 2014 Sep; 126(5):128-34. PubMed ID: 25295657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.